Journal: bioRxiv

Article Title: Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform

doi: 10.1101/2022.06.07.495101

Figure Lengend Snippet: Comparison between the antiviral effects of 5 drug compounds against SARS-CoV-2 infection in primary human epithelial tissue from donor 04401 grown in a PREDICT96-ALI plate: (A) Nirmatrelvir, (B) Molnupiravir, (C) Remdesivir, (D) PF-00835231, and (E) Calpeptin. Antiviral drugs were diluted in Pneumacult ALI medium, added 2 h after infection, and again on days 2 and 4 at the concentrations indicated. Apical sides of tissues were washed with HBSS to collect viral supernatant from which SARS-CoV-2 viral genomes were quantified by RT-qPCR, probing for the N1 gene target. N=4 tissue devices per condition (except untreated samples, n=8). Data collected from the same experiment displayed in and representative of 2 independent experiments. Statistical significance determined by a two-way analysis of variance (ANOVA) with Dunnett’s test for multiple comparisons (comparing to infected/untreated): P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Unlabeled lines indicate no significant different from infected/untreated (gray) line.

Article Snippet: Nirmatrelvir (MedChemExpress), PF-00835231 (MedChemExpress), Molnupiravir (Tocris Bioscience), Calpeptin (Tocris Bioscience) and Remdesivir (Tocris Bioscience) were used in anti- viral screens performed on PREDICT96-ALI tissue.

Techniques: Comparison, Infection, Quantitative RT-PCR

Journal: bioRxiv

Article Title: Predicting clinical outcomes of SARS-CoV-2 drug treatments with a high throughput human airway on chip platform

doi: 10.1101/2022.06.07.495101

Figure Lengend Snippet: Image quantification of SARS-CoV-2 infected tissues nucleocapsid positive (+) cells shows tissue response to 5 drug compounds 6 days post inoculation of SARS-CoV-2 infection in primary human epithelial tissue from donor 04401 grown in a PREDICT96-ALI plate: (A) Nirmatrelvir, (B) Molnupiravir, (C) Remdesivir, (D) PF-00835231, and (E) Calpeptin. Briefly, tissues were stained for nuclei (DAPI) and SARS-CoV-2 nucleocapsid (N) protein. Using the Celigo software, the percentage of nuclei corresponding to cells positive for the nucleocapsid protein was quantified. (F) Controls: Untreated, uninfected (solid gray bar), untreated, infected (patterned bar), and vehicle treated, infected (black bar). (G) Representative monochromatic fluorescence images of uninfected and SARS-CoV-2-infected tissues stained for SARS-CoV-2 nucleocapsid. All data in this figure collected from the same experiment displayed in and representative of 2 independent experiments. Bar graphs show mean ± standard deviation; n=4 tissue devices per condition (except untreated samples, n=8). Statistical significance determined by a one-way analysis of variance (ANOVA) with Dunnett’s test for multiple comparisons (comparing to infected/untreated): no significance (ns), P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Unlabeled bars indicate no significance.

Article Snippet: Nirmatrelvir (MedChemExpress), PF-00835231 (MedChemExpress), Molnupiravir (Tocris Bioscience), Calpeptin (Tocris Bioscience) and Remdesivir (Tocris Bioscience) were used in anti- viral screens performed on PREDICT96-ALI tissue.

Techniques: Infection, Staining, Software, Fluorescence, Standard Deviation

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Results from molnupiravir MOVe-OUT trial in adults with mild-to-moderate COVID-19 [ [14] , [21] , [22] , [23] , [24] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques:

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Subgroups who appeared to have no benefit in hospitalization or death through day 29 with molnupiravir over placebo [ [14] , [21] , [22] , [23] , [24] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques:

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet: Comparative efficacy data of EUA/authorized # drugs for COVID-19 [ [14] , [28] , [29] , [30] , [31] , [32] ].

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: In Vitro

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Infection

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Bioprocessing

Journal: Diabetes & Metabolic Syndrome

Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19 ☆

doi: 10.1016/j.dsx.2022.102396

Figure Lengend Snippet:

Article Snippet: For example-primary outcome was all-cause hospitalization or death for molnupiravir (MOVe-OUT), nirmatrelvir-ritonavir (EPIC-HR) and sotrovimab (COMET-ICE) while it was COVID-19-related hospitalization or death for casirivimab–imdevimab (REGEN-COV), bamlanivimab–etesevimab (BLAZE-1) and remdesivir (PINETREE).

Techniques: Infection